Phase I trials for MRG003 were completed for patients with EGFR-positive tumors (NCT04868344), and reasonable objective response rates (ORRs) were observed for HNSCC (40%) and nasopharyngeal carcinoma (NPC; 44%), although not for CRC patients (0%) [88]. This evidence concerns the gene EGFR and colorectal carcinoma.